A Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study

Overview

The purpose of the research study is (1) to rate the taste, texture, appearance, and mixability of 2 different doses of orange flavored cholestyramine compared to orange flavored Tang, (2) rank the importance of the taste, texture, appearance, and mixability when rating cholestyramine and Tang to determine the accuracy and usefulness of a taste test questionnaire.

Full Title of Study: “A Randomized Single Blind Placebo Controlled Single Research Site Bile Acid Sequestrant Acceptability (BASA) Scale Pilot Validation Study in Generally Healthy Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: February 2010

Detailed Description

The primary objective of this study is to evaluate patient acceptability of 2 doses of orange-flavored generic Questran (cholestyramine) versus orange-flavored Tang Drink Mix (a commercial powdered orange drink without cholestyramine) via 2 BASA scales. A second objective is to assess the 2 different versions of the BASA scale. One version will be unweighted with the score based upon the aggregate score of each acceptability component. A second version will be weighted based upon subjectively-reported importance of the acceptability components. The one main study objective or focus is to determine which version of a BASA scale best differentiates patient acceptability of a bile acid sequestrant (cholestyramine) versus a placebo control powder (containing no bile acid sequestrant) thereby determining which BASA scale is the best validated instrument for future studies in assessing and comparing patient acceptability of bile acid sequestrants.

Interventions

  • Drug: Cholestyramine
    • Cholestyramine 4 grams one time dose
  • Drug: Cholestyramine
    • Cholestyramine 12 grams one dose, one day
  • Drug: Tang
    • Tang one dose one day

Arms, Groups and Cohorts

  • Active Comparator: Cholestyramine 4 grams
  • Active Comparator: Cholestyramine 12 grams
  • Placebo Comparator: Tang

Clinical Trial Outcome Measures

Primary Measures

  • Patient Acceptability of Orange-flavored Generic Questran (Cholestyramine) vs. Tang (a Commercial Powdered Orange Drink) Via 2 Versions of a Bile Acid Sequestrant Acceptability (BASA) Scale.
    • Time Frame: 1 Day
    • The Bile Acid Sequestrant Acceptability Scale has 4 scoring categories: taste, texture, appearance and mixability. Participants rank each category separately. The best possible score for each category is 5 and the worst possible score is 1.

Secondary Measures

  • Weighted vs. Unweighted BASA Scale
    • Time Frame: 1 Day
    • The total aggregate scores for the complete BASA scale were calculated for Cholestyramine 4g, Cholestyramine 12g, and Tang. The total best possible score was 20 and the total worst possible score was 4. A weighted aggregate BASA scale score was also calculated for the Cholestyramine 4g, Cholestyramine 12g, and Tang. The best possible weighted score was 60 and the worst possible weighted score was 4.

Participating in This Clinical Trial

Inclusion Criteria

Subjects or generally healthy volunteers are eligible for inclusion if they meet the following inclusion criteria during the Screening Period:

  • Men or women 18-70 years of age – In general good health. – Subjects are capable of giving informed consent, or if appropriate, have an acceptable surrogate capable of giving consent on the subject's behalf. – Subjects are willing and readily able to be contacted for post-study safety phone call assessments one to seven days after the single study visit. Exclusion Criteria:
  • Prior intolerance to bile acid sequestrants – Women who are either pregnant, or who are not practicing any form of birth control. – Prior gastrointestinal surgery – History of ongoing gastrointestinal symptoms (indigestion, constipation, or diarrhea) – History of bowel obstruction, malabsorption, or irritable bowel syndrome – History of esophageal disease – Current or past history of gall bladder disease – Subjects enrolled in another experimental (interventional) protocol within the past 30 days prior to visit 1. – Diagnosis of diabetes mellitus – Known history of triglyceride levels > 300 mg/dl. – History of alcohol or drug abuse within 1 year of study entry – Alcohol intake that exceeds more than 2 units of alcohol drinks per day – Blood donation within 8 weeks of the study or anticipation of blood donation during the study. – Exposure to bile acid sequestrants (colesevelam HCl, cholestyramine, colestipol within 30 of visit 1). – Any other situation in which the Investigator makes the judgment that participation in the study would not be in the best interest of the study participant, or in the best interest of providing reliable study data.
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: 70 Years

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • Louisville Metabolic and Atherosclerosis Research Center
    • Collaborator
      • Provident Clinical Research
    • Provider of Information About this Clinical Study
      • Harold Bays MD, L-MARC Research Center
    • Overall Official(s)
      • Harold E Bays, MD, Principal Investigator, L-MARC Research Center

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.